Project Grant H8E37872

This $251,493 project grant, awarded by the National Science Foundation's Engineering program (CFDA 47.041), aims to develop optimized pooled testing strategies for efficient prevalence tracking and accurate infection diagnosis during pandemics. The project will focus on three key research thrusts: 1) designing effective sampling and testing algorithms to estimate community prevalence under scarce testing resources, 2) developing optimized pooling and decoding algorithms for compressed...

Numentus Technologies Inc. received a $303,685 Project Grant award from the National Science Foundation on February 15, 2021 to develop rapid planar PCR technology for COVID-19 testing. The award was made under the NSF's Engineering program (CFDA 47.041) to support innovation and excellence in engineering research. Through this funding, Numentus will work to advance the development of planar PCR, a technology that enables highly sensitive COVID-19 detection on a single integrated testing...

The Federal Cooperative Agreement award NU51CK000372, titled "NYS/HRI EPIDEMIOLOGY AND LABORATORY CAPACITY FOR PREVENTION AND CONTROL OF EMERGING INFECTIOUS DISEASES (ELC)", is funded by the Centers for Disease Control and Prevention (CDC) under the Investigations and Technical Assistance program (CFDA 93.283). The $11,171,884 award, effective August 1, 2024 through July 31, 2029, supports a range of public health initiatives aimed at controlling communicable diseases, chronic...

The District of Columbia Department of Health (DC Health) received a $2,130,996 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). This multi-year award, running from August 1, 2024 to July 31, 2029, will support DC Health's efforts to enhance epidemiological surveillance, laboratory testing capabilities, and emergency response for emerging infectious diseases....

This federal Cooperative Agreement award, provided by the Centers for Disease Control and Prevention (CDC) through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323), will support the Florida Department of Health in strengthening public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases within the state. The $3,215,332 award will fund activities to enhance epidemiological surveillance, laboratory testing...

This $505,746 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323) supports the FSM Department of Health and Social Affairs in the Federated States of Micronesia. The award funds a range of public health capacity building activities, including enhancing epidemiological surveillance, laboratory testing capabilities, disease prevention and control programs, and health...

This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program provides $2,011,937.00 to the Virgin Islands Department of Health Group to support the U.S. Virgin Islands Epidemiology Lab Capacity Program. This 5-year project, running from August 1, 2024 to July 31, 2029, aims to strengthen the territory's capacity for detecting, analyzing, testing, and preventing the spread of...

This $1,988,336.00 Cooperative Agreement award from the Centers for Disease Control and Prevention's (CDC) Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program supports the Ohio Department of Health (ODH) in building and strengthening its epidemiology, laboratory, and health information systems to detect, respond, prevent, and control known and (re-) emerging infectious diseases in Ohio. The funding enables ODH to work closely with 111 local health departments...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $40.4 million cooperative agreement to Exela Pharma Sciences, LLC (Exela) to expand industrial base capabilities for COVID-19 response. With a period of performance from May 2022 through May 2034, this cooperative agreement will support Exela under the Research on Chemical and Biological Defense program (CFDA 12.360). Through this cooperative agreement, Exela will further the government's...

DPX Technologies LLC received a $254,536 Project Grant award from the National Science Foundation to develop high-throughput COVID-19 testing under the SBIR PHASE I program. The award, provided by NSF's Directorate for Engineering between April 1, 2021 and September 30, 2021, aims to foster innovation in engineering research and development under the Engineering (47.041) federal grant program. Specifically, DPX Technologies will leverage the funding to create products and services focused on...